Global Ganja Report

Joe Biden's choice of running mate is Kamala Harris, who will bring a more progressive position on cannabis to the ticket. But if Harris today embraces legalization, she too has capitulated to the drug war establishment in the past—a reality her critics have been quick to exploit. A review of her record reveals an overall evolution toward a more enlightened stance.

Nancy Pelosi roused the ire of Mitch McConnell and anti-pot lobbyists when she defended inclusion of a measure to protect cannabis businesses in the House pandemic recovery bill. Does the science actually point to a therapeutic role for cannabis in treatment of COVID-19?

2019 saw advances for cannabis freedom on both the national and global stage—but also some near-misses, from New York state to Mexico, which have left activists frustrated if no less determined. As advocates prepare to carry the fight into 2020, here's a review of what was achieved—or almost achieved—over the past 12 months.

Having cannabis removed from the federal list of controlled substances has long been the holy grail of legalization advocates. Several bills have now been introduced on Capitol Hill to do exactly that. Do any stand a chance of becoming law in the current polarized climate?

There has been significant progress toward cannabis legalization in the United States and globally over the past years, but pockets persist of the most repressive and reactionary prohibition. What are the prospects for expanding cannabis freedom in the coming year?

Advocates increasingly assert that cannabis legalization is not fully realized unless workers are guaranteed their right to employment even if they partake of the herb off-hours. Some states are finally taking measures to rein in the use of urine-test results as an excuse to fire or turn down job applicants.

The US Department of Agriculture is opening an Industrial Hemp Germplasm Repository, in conjunction with upstate New York's Cornell University. The facility is envisioned as a major hub for genetic analysis and research, helping to spur the hemp industry's growth regionally and nationally.

With industry waiting on the FDA to issue regs for CBD products, the agency instead released a statement explaining why it has not yet done so—including fears that the trendy cannabinoid may cause liver damage. But advocates charge that the claim is based on faulty research.